Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547487 | 0.77 | ALDH1A1 (0.39) | GABBR2GABBR1CYP2C19GABRA1GABRB2 | |
| SCHEMBL4020697 | 0.77 | MAPT (0.42) | CYP1A2 | |
| SCHEMBL811190 | 0.77 | POLB (0.39) | GABBR2GABBR1GABRA1GABRB2 | |
| Bromide SCHEMBL4158264 | 0.76 | MAPT (0.41) | CYP1A2 | |
| SCHEMBL30367805 | 0.75 | GABBR2 (0.37) | GABBR2GABBR1GABRA1GABRB2 | |
| SCHEMBL12587964 | 0.74 | GABBR2 (0.32) | GABBR2GABBR1 | |
| SCHEMBL14612293 | 0.74 | GABBR2 (0.39) | GABBR2GABBR1GABRA1GABRB2 | |
| SCHEMBL21327677 | 0.74 | POLB (0.36) | GABBR2GABBR1GABRA1GABRB2 | |
| SCHEMBL708899 | 0.74 | GABBR2 (0.36) | GABBR2GABBR1CYP2C19GABRA1GABRB2 | |
| SCHEMBL31462832 | 0.74 | POLB (0.36) | GABBR2GABBR1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061755-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-12 | — | — | US | disclosed |
| WO-2008109840-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069408-A1 | TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS | TFRC, SLC40A1, FECH | GABBR2 4384/4885GABBR1 4419/4885CYP2C19 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.